9 METERS BIOPHARMA, INC.
9 METERS BIOPHARMA, INC. (NMTR): 5 pipeline candidates · ~3 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.5 months
D/E -2.48 · 0% dilution
Lead: Phase 3
5 candidates
N/A
N/A
A transparent, data-derived signal for 9 METERS BIOPHARMA, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$7.6M
Quarterly Burn
$9.7M
Runway
2.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| larazotide | Phase 2 |
| nm-003 | Preclinical |
| nm-102 | Preclinical |
| nm-136 | Preclinical |
| vurolenatide | Phase 3 |
Frequently asked questions
How many drug candidates are in 9 METERS BIOPHARMA, INC.'s pipeline?
9 METERS BIOPHARMA, INC. (NMTR) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is 9 METERS BIOPHARMA, INC.'s lead drug candidate?
9 METERS BIOPHARMA, INC.'s most advanced tracked candidate is larazotide (Phase 2) for Multi-system Inflammatory Syndrome ("MIS-C").
What is 9 METERS BIOPHARMA, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, 9 METERS BIOPHARMA, INC. has approximately 2.5 months of cash runway.
Get the full picture on 9 METERS BIOPHARMA, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.